(HealthDay)—Inhibition of interleukin-1β (IL-1β) with canakinumab is associated with reduced incident anemia as well as improved hemoglobin levels among patients with baseline anemia, according to research published online March 24 in the Annals of Internal Medicine. Mounica Vallurupalli, M.D., from Brigham and Women’s Hospital in Boston, and colleagues conducted an exploratory analysis of a multicenter...
